{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:52:12Z","timestamp":1791345132117,"version":"4.3.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Empiric antibiotic selection for complicated urinary tract infections (cUTIs) is increasingly complex due to the rising prevalence of multidrug-resistant organisms. We conducted a network meta-analysis (NMA) to compare clinical efficacy and safety among existing empiric treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a frequentist random-effects NMA of randomized controlled trials evaluating single-agent empiric regimens for adults with cUTIs. The primary endpoints were clinical response (CR), microbiological response, and serious adverse events (AEs). Ceftriaxone served as the common comparator.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-seven trials were identified through a systematic search. In the primary analysis of 17 studies published after the year 2000, evaluating agents currently accessible in the United States, in which baseline ceftriaxone non-susceptibility among Enterobacterales averaged approximately 15%. Ceftriaxone demonstrated CR rates comparable to broader-spectrum alternatives. Although some agents achieved higher microbiological eradication, these differences did not translate into superior clinical cure rates. Safety profiles were stable across antibiotic classes, with no significant differences in serious AEs compared to cephalosporins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ceftriaxone remains an effective empiric option for hemodynamically stable adults with cUTIs in settings with comparable resistance prevalence. These findings provide evidence to support antimicrobial stewardship efforts that prioritize narrower-spectrum agents, preserving broader-spectrum therapies for patients at highest risk for resistant pathogens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag592","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:30:43Z","timestamp":1790335843000},"source":"Crossref","is-referenced-by-count":0,"title":["A Systematic Review and Network Meta-analysis of Empirical Antibiotics for Complicated Urinary Tract Infections"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0496-4726","authenticated-orcid":false,"given":"Lior","family":"Cohen-Yatziv","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Illinois Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9928-2105","authenticated-orcid":false,"given":"Emily","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Library of the Health Sciences, University of Illinois Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6258-2091","authenticated-orcid":false,"given":"Ruiwen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Center for Biostatistics and Data Science, Washington University School of Medicine , St. Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4280-9804","authenticated-orcid":false,"given":"Maria Cristina","family":"Vazquez Guillamet","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University in St. Louis School of Medicine , St. Louis, Missouri ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, Washington University in St. Louis School of Medicine , St. Louis, Missouri ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"2026100623463921100_ofag592-B1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"2026100623463921100_ofag592-B2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","article-title":"Epidemiology, definition and treatment of complicated urinary tract infections","volume":"17","author":"Wagenlehner","year":"2020","journal-title":"Nat Rev Urol"},{"key":"2026100623463921100_ofag592-B3","doi-asserted-by":"crossref","first-page":"ofab591","DOI":"10.1093\/ofid\/ofab591","article-title":"Descriptive epidemiology and outcomes of hospitalizations with complicated urinary tract infections in the United States, 2018","volume":"9","author":"Zilberberg","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026100623463921100_ofag592-B4","author":"Trautner"},{"key":"2026100623463921100_ofag592-B5","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMcp1104429","article-title":"Uncomplicated urinary tract infection","volume":"366","author":"Hooton","year":"2012","journal-title":"N Engl J Med"},{"key":"2026100623463921100_ofag592-B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2013.09.003","article-title":"Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden","volume":"28","author":"Foxman","year":"2014","journal-title":"Infect Dis Clin North Am"},{"key":"2026100623463921100_ofag592-B7","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026100623463921100_ofag592-B8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14656566.2024.2446632","article-title":"Complicated urinary tract infections: an update of new and developing antibiotics","volume":"26","author":"Guerriero","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"2026100623463921100_ofag592-B9","doi-asserted-by":"crossref","first-page":"107208","DOI":"10.1016\/j.ijid.2024.107208","article-title":"Epidemiology and antimicrobial resistance trends of pathogens causing urinary tract infections in Mwanza, Tanzania: a comparative study during and after the implementation of the National Action Plan on Antimicrobial Resistance (2017-2022)","volume":"147","author":"Silago","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2026100623463921100_ofag592-B10","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S1473-3099(24)00149-X","article-title":"Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study","volume":"24","author":"Walker","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026100623463921100_ofag592-B11","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajic.2015.05.020","article-title":"Retrospective cohort study of inappropriate piperacillin-tazobactam use for lower respiratory tract and skin and soft tissue infections: opportunities for antimicrobial stewardship","volume":"43","author":"Havey","year":"2015","journal-title":"Am J Infect Control"},{"key":"2026100623463921100_ofag592-B12","doi-asserted-by":"crossref","first-page":"e2418923","DOI":"10.1001\/jamanetworkopen.2024.18923","article-title":"Trends in empiric broad-spectrum antibiotic use for suspected community-onset sepsis in US hospitals","volume":"7","author":"Rhee","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026100623463921100_ofag592-B13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/jhm.13390","article-title":"Outcomes associated with initial narrow-spectrum versus broad-spectrum antibiotics in children hospitalized with urinary tract infections","volume":"19","author":"Markham","year":"2024","journal-title":"J Hosp Med"},{"key":"2026100623463921100_ofag592-B14","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/cid\/ciab637","article-title":"Association of adverse events with antibiotic treatment for urinary tract infection","volume":"74","author":"Butler","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026100623463921100_ofag592-B15","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.cmi.2022.05.016","article-title":"Antibiotic management of urinary tract infections in the post-antibiotic era: a narrative review highlighting diagnostic and antimicrobial stewardship","volume":"29","author":"Abbott","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026100623463921100_ofag592-B16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-14-13","article-title":"A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance","volume":"14","author":"Bell","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2026100623463921100_ofag592-B17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/8755122520964435","article-title":"Analysis of community-acquired urinary tract infection treatment in pediatric patients requiring hospitalization: opportunity for use of narrower spectrum antibiotics","volume":"37","author":"Stultz","year":"2021","journal-title":"J Pharm Technol"},{"key":"2026100623463921100_ofag592-B18","doi-asserted-by":"crossref","first-page":"e2444495","DOI":"10.1001\/jamanetworkopen.2024.44495","article-title":"Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement","volume":"7","author":"Nelson","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026100623463921100_ofag592-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"Netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"key":"2026100623463921100_ofag592-B20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s11606-024-08674-1","article-title":"Identifying the best initial oral antibiotics for adults with community-acquired pneumonia: a network meta-analysis","volume":"39","author":"Kurotschka","year":"2024","journal-title":"J Gen Intern Med"},{"key":"2026100623463921100_ofag592-B21","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.cmi.2025.06.033","article-title":"Empiric antibiotic therapy for moderate to severe community-acquired pneumonia: a systematic review and network meta-analysis","volume":"31","author":"Ghadimi","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026100623463921100_ofag592-B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026100623463921100_ofag592-B23","author":"Veritas Health Innovation"},{"key":"2026100623463921100_ofag592-B24","author":"EndNote"},{"key":"2026100623463921100_ofag592-B25","volume-title":"International council for harmonisation of technical requirements for pharmaceuticals for human use","author":"International Council for Harmonisation. Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2)","year":"2016"},{"key":"2026100623463921100_ofag592-B26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/9781119536604.ch8","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"2026100623463921100_ofag592-B27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/9781119536604.ch14","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Sch\u00fcnemann","year":"2019"},{"key":"2026100623463921100_ofag592-B28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/87551225221121252","article-title":"Ceftriaxone 1 g versus 2 g daily for the treatment of Enterobacterales bacteremia: a retrospective cohort study","volume":"38","author":"Baalbaki","year":"2022","journal-title":"J Pharm Technol"},{"key":"2026100623463921100_ofag592-B29","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/AAC.24.5.812","article-title":"Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers","volume":"24","author":"Meyers","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100623463921100_ofag592-B30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026100623463921100_ofag592-B31","doi-asserted-by":"crossref","first-page":"ofae193","DOI":"10.1093\/ofid\/ofae193","article-title":"Real-world effectiveness of intravenous and oral antibiotic stepdown strategies for gram-negative complicated urinary tract infection with bacteremia","volume":"11","author":"Veillette","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026100623463921100_ofag592-B32","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1093\/cid\/ciy1121","article-title":"Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America","volume":"68","author":"Nicolle","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026100623463921100_ofag592-B33","doi-asserted-by":"crossref","first-page":"dlae188","DOI":"10.1093\/jacamr\/dlae188","article-title":"Urinary tract infections: a retrospective cohort study of (mis)matching antimicrobial therapy and clinical outcome among Finnish adults","volume":"6","author":"Patjas","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026100623463921100_ofag592-B34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/21681805.2022.2123039","article-title":"Community-onset urosepsis: incidence and risk factors for 30-day mortality \u2013 a retrospective cohort study","volume":"56","author":"Holmbom","year":"2022","journal-title":"Scand J Urol"},{"key":"2026100623463921100_ofag592-B35","doi-asserted-by":"crossref","first-page":"11927","DOI":"10.1038\/s41598-021-90949-2","article-title":"Prospective cohort study on hospitalised patients with suspected urinary tract infection and risk factors por multidrug resistance","volume":"11","author":"Garcia-Bustos","year":"2021","journal-title":"Sci Rep"},{"key":"2026100623463921100_ofag592-B36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijid.2022.03.052","article-title":"Regional differences in antibiotic-resistant Enterobacterales urine isolates in the United States: 2018-2020","volume":"119","author":"Aronin","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026100623463921100_ofag592-B37","doi-asserted-by":"crossref","first-page":"e240214","DOI":"10.57264\/cer-2024-0214","article-title":"Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis","volume":"14","author":"Wagenlehner","year":"2025","journal-title":"J Comp Eff Res"},{"key":"2026100623463921100_ofag592-B38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1017\/S0266462312000086","article-title":"The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies","volume":"28","author":"Morrison","year":"2012","journal-title":"Int J Technol Assess Health Care"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag592\/71401579\/ofag592.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag592\/71401579\/ofag592.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag592\/71401579\/ofag592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:46:48Z","timestamp":1791344808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag592\/8836495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag592","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,26]]},"article-number":"ofag592"}}